1800 244 735

Helpline (02) 9874 9777

Stand By for Oz Buzz

The Huntington’s disease World Congress starts this weekend. Follow @HDBuzzFeed for live updates, check out HDBuzz.net for the latest news and videos, and send us your questions for the top HD scientists.

Oz Buzz – live from The World Congress on Huntington’s disease

The World Congress on Huntington’s disease is the biggest international meeting of HD scientists, care professionals and family members. The 2011 World Congress begins in Melbourne, Australia this Sunday – 11th September.

Your HDBuzz editors – Dr Jeff Carroll and Dr Ed Wild – have teamed up with Emmy award-winning broadcaster Charles Sabine to present Oz Buzz – reporting live from the World Congress. In the spirit of HDBuzz, we’ll be bringing the most exciting scientific news to the global HD community.

Follow HDBuzzFeed on Twitter for live updates

Throughout the World Congress, Ed and Jeff will be using Twitter to post plain language news updates, in real time, from within the science sessions. So if you want the very hottest news, as it happens, follow @HDBuzzFeed.

Daily updates at HDBuzz.net

Each evening, we’ll post a new article to HDBuzz.net, containing all the day’s science updates from the Congress. Like any HDBuzz article, you’ll be able to read it at HDBuzz.net, on the community websites that use the HDBuzz feed, and in your inbox, if you’ve signed up to receive our email updates.

Oz Buzz live on stage

On the evenings of Monday 12th and Tuesday 13th September, Jeff, Ed and Charles will present Oz Buzz live, featuring the news headlines from the day, and in-depth interviews with top HD researchers – all in easy-to-understand language – plus some entertaining features on the social life behind the Congress and the host city of Melbourne.

Video of the live sessions will be available to watch at HDBuzz.net within a few hours after the session.

Oz Buzz needs you!

We’ll be interviewing three top scientists each night – and we want you to send us questions for them. Now’s your chance to get an answer to that burning question you’ve been wondering about, straight from the horse’s mouth. The scientists we’ll be interviewing, and the areas we’ll be covering, are:

    n

  • Dr Frank Bennett of Isis Pharmaceuticals – gene silencing therapy

  • n

  • Dr Tony Hannan of Florey Neuroscience Institutes, Melbourne – environmental factors that can influence HD onset and progression

  • n

  • Prof Leslie Thompson of University of California Irvine – how our DNA and the huntingtin protein are chemically modified by cells

  • n

  • Dr Rachael Scahill of University College London – how magnetic resonance imaging will help us to run clinical trials in HD

  • n

  • Prof Steve Finkbeiner of Gladstone Institute of Neurological Disease – how cells handle harmful proteins

  • n

  • Prof Paul Muchowski of Gladstone -targeting the immune system to help brain cells to survive

  • n

You can send us your questions in several ways:

    n

  • By email to worldcongress@hdbuzz.net

  • n

  • Tweet us – @HDBuzzFeed

  • n

  • Record your question on YouTube and send us the link by email or tweet

  • n

Please tell us your name (or nickname) and what country you’re in. Send your questions any time – before or during the Congress – and the best ones will be asked during the live session.

We hope you enjoy our World Congress coverage – we aim to make it the most accessible international research meeting the global HD community has seen.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Updates from the EHDN Meeting 2021

Published date: 28 October, 2021

Last month, the Huntington’s disease (HD) research community, patients and other stakeholders met online at the European Huntington’s disease network (EHDN) conference. Despite the ongoing global pandemic, there is a tremendous amount of work underway in labs and clinics around the world as researchers continue to better understand HD and how we might best treat ... Read more

Real talk: Q&A with Roche about GENERATION-HD1

Published date: 28 September, 2021

At the end of day 1 of the European Huntington’s Disease Network (EHDN) conference, the HDBuzz team (minus one) sat down for a zoom chat with the team at Roche to have a frank, candid discussion about the recent halting of GENERATION-HD1, the Phase 3 clinical trial that was testing the ability of the antisense ... Read more

Another tool in the box: Creation of a molecular “dimmer switch” advances gene editing

Published date: 30 August, 2021

A team of scientists recently created an innovative genetic system where a drug taken by mouth could be used to control the action of a gene editor, like those used in CRISPR systems. This has useful applications for research studies in cells and animals, and perhaps most importantly, could lead to improvements in the safety ... Read more

Unpacking recent gene therapy press

Published date: 16 August, 2021

A recent announcement from Voyager Therapeutics outlined a shift in the company’s strategy towards an exciting new technology for gene therapy delivery. Unfortunately this also means that in the short term, they have dropped previous plans to test an HD gene therapy in people with HD. While this news is disappointing, the decision to embrace ... Read more

Does blood hold the key to testing treatments earlier in HD patients?

Published date: 4 August, 2021

Researchers at Johns Hopkins led by Wenzhen Duan have developed a non-invasive way to track progression of Huntington’s disease (HD) which could be used before patients even start showing symptoms. Using a type of brain scan called an MRI, the researchers have shown that in mouse models of HD they can accurately measure the amount ... Read more

A first for CRISPR gene editing could have wider applications for human disease

Published date: 21 July, 2021

A recent clinical trial successfully tested the safety of CRISPR gene editing to reduce the amount of a toxic protein in patients with Familial Transthyretic (TTR) Amyloidosis. Although this study is unrelated to Huntington’s disease, it’s a first for gene editing, and the results could have implications for HD and other brain disorders. CRISPR-Cas9 Clustered ... Read more